Zenth Pharma's clinical division designs, manages, and executes globally compliant trials spanning Phase I–IV. We leverage AI-driven patient stratification, decentralized trial frameworks, and real-world evidence to accelerate therapeutic development safely and ethically.
A diversified portfolio addressing high-unmet medical needs across oncology, neurology, rare diseases, and cardiovascular medicine.
Advanced solid tumors with PD-L1 & MSI-H biomarkers
Early-stage Alzheimer's disease & cognitive decline
CRISPR-based intervention for inherited metabolic disorders
Non-valvular atrial fibrillation stroke prevention
Respiratory viral pathogens with pan-coronavirus activity
Long-term safety & efficacy of approved biologic in autoimmune conditions
Our clinical operations integrate cutting-edge technology with rigorous scientific standards to optimize trial efficiency, patient safety, and data integrity.
Machine learning models analyze multi-omic profiles and EHR data to identify ideal trial populations, reducing screen failure rates by up to 64%.
Hybrid trial designs utilizing direct-to-patient shipments, telemedicine visits, and wearable biomarker tracking to improve retention and accessibility.
We embed RWE collection protocols into pivotal trials to bridge clinical data with post-market outcomes, accelerating regulatory submissions.
Pre-planned interim analyses and Bayesian modeling allow dynamic cohort adjustments, dose optimization, and futility stopping without compromising integrity.
Every protocol undergoes multi-tiered ethical review and aligns with international regulatory frameworks. Patient safety and data sovereignty are non-negotiable.
Partner with Zenth Pharma to advance transformative therapies. We offer competitive site funding, dedicated clinical research coordinators, streamlined eTMF access, and transparent milestone payments.